- Prajish Iyer1,5,
- Savio George Barreto3*,
- Malika Ranjan1*,
- Nilesh Gardi2,5,
- Sameer Salunkhe4,5,
- Bikram Sahoo1,
- Pratik Chandrani1,
- Shilpee Dutt4,5,
- Mukta R. Ramadwar2,
- Vikram Chaudhari3,
- Shailesh V. Shrikhande3,
- Amit Dutt1,5#
- 1Integrated Genomics Laboratory, Advanced Centre for Treatment Research Education In Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, Maharashtra 410210, INDIA
- 2Department of Pathology, Tata Memorial Centre, Ernest Borges Marg, Parel, Mumbai 400012, INDIA
- 3Department of Gastrointestinal and Hepato-Pancreato-Biliary Surgical Oncology, Tata Memorial Centre, Ernest Borges Marg, Parel, Mumbai 400012, INDIA
- 4Shilpee laboratory, Advanced Centre for Treatment Research Education In Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, Maharashtra 410210, INDIA
- 5Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, INDIA
Can J Biotech, Volume 1, Special Issue, Page 73, DOI: https://doi.org/10.24870/cjb.2017-a60
*Corresponding author: firstname.lastname@example.org
Introduction: Gallbladder cancer is relatively a rare lethal malignancy with dismal prognosis. While in India there is high incidence (3.9-8.6/1, 00,000) with majority of patients having advanced disease. Recent developments in next generation sequencing technologies have enabled the discovery of new molecular therapeutic targets in many human cancers.
Objectives: Interrogate the landscape of somatic alterations in Indian gall bladder cancer using whole exome sequencing technology.
Material and Methods: We interrogated the coding region of 27(10 paired and 7 unpaired) Indian gall bladder cancer samples using whole exome sequencing at an average coverage of 100X and above. We further validated the findings using an additional set of 27 FFPE samples.
Results: Using a bioinformatics filtering approach, we identify a total of 5060 somatic variants found across 17 tumors consisted of 3239 missense, 1449 silent, 131 nonsense, 135 indels and 106 splice site mutations The average mutation rate considering the paired tumors is about 7.7 mutations/mb. We found TP53 (35.2%), ERBB2 (17.6%), SF3B1 (17.6%), ATM (17.6%) and AKAP11 (17.6%) mutations in more than two samples by exome sequencing analysis. Furthermore, we examined our exome sequencing data for identifying Salmonella sequences as well as presence of 143 HPV types using computation subtraction based on HPVDetector. Based on our evaluation we found association of typhoidal Salmonella strains in 11 of 26 gall bladder cancer samples and non-typhoidal Salmonella species in 12 of 26 samples, 6 samples were co-infected with both.
Conclusions: The profiling of somatic alterations and identification of non typhoidal Salmonella traces may aid in changing the current treatment paradigm of gall bladder cancer.